在立陶宛的HS患者的并发症,临床表现,亚型和治疗
Tadas Raudonis1,2, Austėja Šakaitytė3, Tomas Petras Vileikis1
1Clinic of Infectious Disease and Dermatovenereology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. Čiurlionio g. 21, 03101 Vilnius, Lithuania.
Journal of clinical medicine
|July 13, 2024
概括
补腺炎 (HS) 的严重程度与炎症和代谢并发症相关. 生物治疗显著改善了HS得分,比系统性抗生素更大.
科学领域:
- 皮肤病学 皮肤病学
- 遗传学 是一个遗传学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 补腺炎 (HS) 是一种慢性炎症性皮肤疾病.
- HS与众多的并发症有关.
- 目前的治疗包括抗生素,激素治疗,免疫调节剂,手术和并发症治疗.
研究的目的:
- 为了评估HS患者的并发症.
- 为了确定临床表现的亚型.
- 评估用于HS的治疗方法.
主要方法:
- 使用了欧洲上腺炎补充性基金会注册表的问卷.
- 在维尔纽斯大学医院皮肤神经病学中心评估患者.
- 包括49名被诊断为HS的患者.
主要成果:
- 61.22%的患者患有并发症.
- 在家族炎症病史和HS严重程度 (Hurley阶段) 之间发现了强烈的正相关性.
- 代谢并发症与HS严重程度 (Hurley阶段) 有显著的相关性.
- 生物治疗在IHS4评分 (7.38到3.22,p <0.05) 中显著改善.
- 非生物治疗没有显著改善IHS4得分 (6.21至5.42,p > 0.05).
结论:
- 炎症性疾病和代谢并发症的家族病史与HS严重程度密切相关.
- 与系统性抗生素相比,生物疗法在改善HS得分方面表现出卓越的疗效.
相关概念视频
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
156
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
156
Drugs for Treatment of Constipation-Predominant IBS
154
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
154
Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
Chronic Bowel Disorders: Introduction
439
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
439
COPD: Pathogenesis and Clinical Features
257
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
257


